BridgeBio Pharma (BBIO) Q2 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.78

Estimate

-$0.58

Surprise

-33.9%

Revenue (period 2026-06-30)

$243.7M

Score at report (before → after)

5.3 → 5.4/10

Revenue source: xbrl.

BridgeBio Pharma (BBIO) reported a wider loss than forecast — adjusted EPS of -$0.78 against the -$0.58 estimate (a 33.9% shortfall). TrendMatrix's engine moved from Buy (Wait) (5.3/10) to Sell at 5.4/10 after the report — the engine's score rose despite the miss.

TrendMatrix currently rates BBIO Sell at 6.0/10.

1 of the last 4 quarters beat the estimate; this quarter's -33.9% surprise compares with a -28.2% four-quarter average. Next scheduled report: 2026-10-28.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$64.92

Price target

$98.14

Stop

$60.97

Upside to target

+51.2%

Reward-to-risk

7.6:1

Model outputs from TrendMatrix’s engine as of 2026-10-14 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$12.37B

P/E (fwd)

2190.3

52-week range

$52.75–$93.42

Off 52-week high

30.5%

RSI (14)

45

Volume vs avg

0.57×

Score today

6.0/10